Peter Pitts Discusses Expedited Reviews and the Current State of Drug Development

Peter Pitts:
Regardless of what you want to call it, whether it’s expedited review or special protocols, limited use medicines, the theory is, “How can the FDA help bring important therapies to the market faster?” And, there are a lot of pieces to that puzzle.

At the end of the day, the agency still has to meet with the sponsor, who still has to have data. They have to meet and decide how to move forward.

There are two issues that also have to come into this conversation:
  1. The patient voice
  2. Benefit / risk profile
Those are two things that really are not usually discussed. Generally speaking, in this type of conversation what comes about in the discussion is time. How quickly can something happen? Obviously faster is better than slower, but you don’t want to ever sacrifice proper review.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Managed Care Magazine Launches Attack on Orphans

Managed Care Magazine Launches Attack on Orphans

As the FDALawBlog points out, in some cases, a single orphan drug designation can result in multiple periods of orphan dr...  Read more

Cut FDA red tape so doctors can better treat patients

Cut FDA red tape so doctors can better treat patients

Off-label prescribing has already has saved thousands of lives. The FDA ought to make it easier for doctors and patients ...  Read more

A Social Media Manifesto
  • Journal of Commercial Biotechnology
  • 01/01/2014

A Social Media Manifesto

...  Read more

DRUGWONKS BLOG